Generex Announces Acquisition of Additional 38% of Subsidiary Olaregen Therapeutix in an Up-Market Transaction with a Share Exchange of GNBT Stock at $2.50
Generex Now Owns 99% of Subsidiary Olaregen Therapeutix Generex Satisfies Notes for $138,000 and $900,000 to clear debt NuGenerex Immuno-Oncology Spin-out Evaluating Acquisition of a Hospital Network Completed Audit of Direct-to-Patient Pharmacy Business MIRAMAR, Fla., […]